Veterans Health Administration, Tennessee Valley Healthcare System Geriatric Research Education Clinical Center, Nashville, TN
Jennifer A. Lewis , Jason Denton , Michael E. Matheny , Christopher G. Slatore , Amelia W Maiga , Eric Grogan , Pierre P. Massion , Robert H. Sherrier , Robert S. Dittus , Laura Keohane , Christianne L. Roumie , Sayeh Nikpay
Background: Low-dose CT (LDCT) is an effective means for early lung cancer detection, but is often underutilized. An estimated 900,000 Veterans are eligible for lung cancer screening. We are the first to describe national lung cancer screening utilization trends in the Veterans Health Administration (VHA). Methods: We assembled a retrospective cohort of patients within the VHA’s Observational Medical Outcomes Partnership (OMOP) Common Data Model who underwent lung cancer screening. LDCT scans with Common Procedure Terminology (CPT) codes G0297 or 71250 from January 1, 2011 to May 31, 2018 were eligible for inclusion. We further selected exams described as “lung cancer screening,”“screening,” or “LCS.” We used descriptive statistics with frequencies and medians to calculate the total exams per Veteran and evaluate utilization trends over time and by region. Results: At initial screening, Veterans had a median age of 66 (IQR 61, 70), 95% were male, 76% Caucasian. From January 1, 2011 to May 31, 2018, 75 VHA facilities performed 129,363 LDCT exams for lung cancer screening; 87,950 (68%) initial and 41,413 (32%) subsequent exams. Screening has increased over time (226 in 2011-2012; 7848 in 2013-2014; 41,225 in 2015-2016; 80,064 in 2017 until May 31, 2018) in all regions. Providers in primary care/internal medicine (56%), family medicine (16%), pulmonology (6%), oncology (0.3%), other specialties (21%) ordered screening exams. Conclusions: Lung cancer screening with low-dose CT within the VHA increased over time within all geographic regions. Future strategies aimed at the Veteran, provider, and healthcare system levels are needed to increase lung cancer screening utilization among eligible Veterans.
Year | Northeast n (%) | South n (%) | Mid-West n (%) | West n (%) | Total |
---|---|---|---|---|---|
2011-12 | 1(0) | 225(0.4) | 0 | 0 | 226(0.2) |
2013-14 | 2,325(7.5) | 4,007(6.7) | 1,200(4.5) | 316(2.7) | 7848(6.1) |
2015-16 | 10,095(32.6) | 19,314(32.1) | 8,283(31.2) | 3,533(30.2) | 41,225(31.9) |
2017-18* | 18,500(59.8) | 36,665(60.9) | 17,031(64.2) | 7,868(67.2) | 80,064(61.9) |
Total | 30,921(100) | 60,211(100) | 26,514(100) | 11,717(100) | 129,363(100) |
*Data collected through May 31, 2018
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Jennifer Bail
2023 ASCO Quality Care Symposium
First Author: Kyle Austin Sugg
2023 ASCO Annual Meeting
First Author: Sasmith R. Menakuru
2022 ASCO Quality Care Symposium
First Author: Laura Miotke